Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity
Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 6162-6171
DOI: 10.1111/dom.70773 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 28.04.2026. Verfasst von Andreea Ciudin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Nutrition, Vall D'Hebron University Hospital, Barcelona, Spain. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Glucagon-Like Peptide-1 Receptor Agonists, Overweight, Semaglutide. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Aims
Tirzepatide, an injectable glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist (RA), is approved for weight management in several regions. Oral GLP‐1 RAs, such as semaglutide, are under investigation to improve convenience, acceptance and adherence versus injectable formulations. Currently, no studies have compared the efficacy and safety of tirzepatide with oral semaglutide for weight management. This study aimed to indirectly compare the efficacy and safety of weekly injectable tirzepatide 5, 10 and 15 mg for weight management in obesity and overweight versus daily oral semaglutide 50 mg. Materials and Methods Pivotal trials SURMOUNT‐1 (tirzepatide, Week 72) and OASIS 1 (oral semaglutide, Week 68) were compared using multilevel network meta‐regression (ML‐NMR) to adjust for differences in sex, ethnicity and outcome baselines between trial populations. Participants were adults without type 2 diabetes and with obesity (BMI ≥ 30 kg/m 2 ), or overweight (BMI ≥ 27 kg/m 2 ) with ≥ 1 obesity‐related complication.
Results
Tirzepatide 10 and 15 mg were associated with statistically significantly greater reductions in weight (mean difference: −4.48% [−6.35, −2.61] and −5.59% [−7.52, −3.77]) and waist circumference (−3.60 cm [−5.59, −1.72] and −4.32 cm [−6.30, −2.40]), and higher odds of achieving ≥ 5%/10%/15%/20% weight reduction compared with oral semaglutide. Cardiometabolic benefits and safety profiles were improved or generally comparable for tirzepatide versus oral semaglutide.
Conclusions
This ML‐NMR provides an indirect comparison of injectable tirzepatide with oral semaglutide for weight management. Tirzepatide was associated with statistically significantly greater weight and waist circumference reduction versus oral semaglutide and improved or similar cardiometabolic benefits and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology and Nutrition, Vall D'Hebron University Hospital, Barcelona, Spain.
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
- Costello Medical, Manchester, UK.
ORCID-Profile: Andreea Ciudin, Erin Johansson, Sarah Zimner-Rapuch, Georgios K Dimitriadis, Mathias Hempfling, Laura J Clark, Ludi Fan, Helene Sapin
Förderung
- Eli Lilly and Company
Zitieren
APA
Ciudin, A., Johansson, E., Zimner-Rapuch, S., Dimitriadis, G. K., Hempfling, M., Clark, L. J., Fan, L., & Sapin, H. (2026). Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity. Diabetes, Obesity and Metabolism, 28(7), 6162-6171. https://doi.org/10.1111/dom.70773
Vancouver
Ciudin A, Johansson E, Zimner-Rapuch S, Dimitriadis GK, Hempfling M, Clark LJ, et al. Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity. Diabetes, Obesity and Metabolism. 2026;28(7):6162-6171. doi:10.1111/dom.70773
BibTeX
@article{Ciudin2026,
author = {Ciudin, Andreea and Johansson, Erin and Zimner-Rapuch, Sarah and Dimitriadis, Georgios K and Hempfling, Mathias and Clark, Laura J and Fan, Ludi and Sapin, Helene},
title = {Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {7},
pages = {6162--6171},
doi = {10.1111/dom.70773}
}
EUVIMED